Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries (OP: LOBEF ) 0.0145 +0.0005 (+3.57%) Streaming Delayed Price Updated: 11:23 AM EST, Nov 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 23,416 Open 0.0120 Bid (Size) N/A (0) Ask (Size) N/A (0) Prev. Close 0.0140 Today's Range 0.0120 - 0.0145 52wk Range 0.0101 - 0.0225 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Lobe Sciences, Ltd. Announces the Appointment of Enclave Capital and Peak Asset Management to Fund Clinical Trials of Conjugated Psilocin™ October 16, 2024 From Lobe Sciences, Ltd. Via Business Wire Lobe Sciences and Alera Pharma Announce Issuance of U.S. Patent for Conjugated Psilocin™ October 02, 2024 From Lobe Sciences, Ltd. Via Business Wire Performance YTD +4.32% +4.32% 1 Month -5.23% -5.23% 3 Month -12.12% -12.12% 6 Month +6.62% +6.62% 1 Year +22.88% +22.88% More News Read More Lobe Sciences Announces Creation of Wholly Owned Subsidiary, Alera Pharma, Inc. August 15, 2024 From Lobe Sciences Ltd Via Business Wire Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip! March 01, 2023 Via TheNewswire.com Lobe Sciences Announces Appointment of a New Board of Directors and Executive Management Team August 12, 2024 From Lobe Sciences Ltd Via Business Wire Lobe Sciences Announces Update June 04, 2024 From Lobe Sciences Ltd. Via Business Wire Wesley Ramjeet to Join Lobe Sciences’ Board of Directors, Bringing Decades of Strategic Financial Expertise June 03, 2024 From Lobe Sciences Ltd. Via Business Wire Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors May 31, 2024 From Lobe Sciences Ltd. Via Business Wire Former Merck Director and Vanderbilt Vice-Chancellor, Dr. Harry Jacobson, to Join Lobe Sciences Board of Directors May 30, 2024 From Lobe Sciences Ltd. Via Business Wire Lobe Sciences Ltd. and Clearway Global Announce Change of Control and Focus on Creating Value for Shareholders May 21, 2024 From Lobe Sciences Ltd. Via Business Wire Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More January 15, 2024 Via Benzinga Lobe Sciences Provides Company Review of 2023 January 08, 2024 From Lobe Sciences Ltd. Via Business Wire Lobe Sciences Provides Update on L-130 Clinical Program December 07, 2023 From Lobe Sciences Ltd. Via Business Wire Lobe Sciences Provides Update on L-130 Oral Psilocin Compound December 05, 2023 From Lobe Sciences Ltd. Via Business Wire Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company September 14, 2023 From Lobe Sciences Ltd. Via Business Wire Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More July 04, 2023 Via Benzinga This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches June 28, 2023 Via Benzinga Lobe Sciences Initiates Phase 1 Clinical Trial of L-130 June 27, 2023 From Lobe Sciences Ltd. Via Business Wire Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer June 07, 2023 From Lobe Sciences Ltd. Via Business Wire Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™ May 17, 2023 From Lobe Sciences Ltd. Via Business Wire Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More April 24, 2023 Via Benzinga Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up April 20, 2023 Via Benzinga Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip! February 28, 2023 Via Benzinga Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic January 27, 2023 Via Benzinga Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry January 26, 2023 Via FinancialNewsMedia Topics Economy Exposures Supply Chain Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
